Provided by Tiger Trade Technology Pte. Ltd.

Legend Biotech

21.82
+0.56002.63%
Post-market: 22.090.2685+1.23%19:41 EDT
Volume:1.42M
Turnover:31.26M
Market Cap:4.24B
PE:-43.57
High:22.37
Open:21.44
Low:21.38
Close:21.26
52wk High:37.50
52wk Low:16.24
Shares:194.49M
Float Shares:90.19M
Volume Ratio:0.58
T/O Rate:1.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5008
EPS(LYR):-1.6200
ROE:-8.08%
ROA:-1.92%
PB:3.45
PE(LYR):-13.47

Loading ...

Legend Biotech says Phase 1 trial shows 100% response rate at higher dose for in vivo CAR-T LB2501 in R/R B-NHL

Reuters
·
Jun 14

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

GlobeNewswire
·
Jun 14

Oncology Deal Shock Creates Three Very Different Stock Setups

Simply Wall St.
·
Jun 09

Legend Biotech's Stock Surge: From 40% Gains in Two Months to a Single-Day 40% Jump

Stock News
·
Jun 05

UBS Adjusts Legend Biotech Price Target to $49 From $31, Maintains Buy Rating

MT Newswires Live
·
Jun 04

Legend Biotech Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 03

Legend Biotech Corporation : H.c. Wainwright Raises Target Price to $65 From $50

THOMSON REUTERS
·
Jun 03

Barclays Remains a Buy on Legend Biotech (LEGN)

TIPRANKS
·
Jun 03

U.S. RESEARCH ROUNDUP-Aveanna Healthcare, Palo Alto, Ulta Beauty

Reuters
·
Jun 03

BUZZ-Genscript hits 4-week high on associate's promising blood cancer cell therapy

Reuters
·
Jun 03

Genscript Biotech Soars on Positive Clinical Data from Affiliate Legend Biotech

Stock News
·
Jun 03

Legend Biotech ADRs Climb on Preliminary Study Results for Non-Hodgkin Lymphoma Treatment

Dow Jones
·
Jun 03

This Is Why Legend Biotech Stock (LEGN) Was Up Today

TIPRANKS
·
Jun 03

Legend Biotech rises 29.5%

TIPRANKS
·
Jun 03

Legend Biotech presents preliminary clinical data for LB2501 at EHA Congress

TIPRANKS
·
Jun 02

Legend Biotech reports 100% response rate in Phase 1 LB2501 in vivo CAR-T trial for relapsed/refractory NHL patients at higher dose cohort

Reuters
·
Jun 02

BRIEF-Legend Biotech Announces Promising Preliminary Clinical Data For LB2501

Reuters
·
Jun 02

Legend Biotech Announces Late-Breaking Oral Presentation at Eha 2026 Showcasing Initial Phase 1 in Vivo CAR-T Data With Lb2501 in Non-Hodgkin Lymphoma (Nhl)

THOMSON REUTERS
·
Jun 02

Legend Biotech: No Dose-Limiting Toxicities, Serious Adverse Events, or Neurotoxicity Reported

THOMSON REUTERS
·
Jun 02

Legend Biotech: 100% Orr (6/6) Observed in Dose Level 2 Cohort, Including Cr Rate of 83.3% (5/6) in Patients With Relapsed/ Refractory Nhl

THOMSON REUTERS
·
Jun 02